It remains unclear whether severe liver immune-related adverse events (liver-irAEs) can affect the prognosis in nonsmall cell lung carcinoma (NSCLC) patients. Of the 365 NSCLC patients treated with im
FCS files from ICI colitis patients, Ulcerative Colitis patients, and Healthy controls. Normalized fcs files for each patient from biopsy samples. Live cells were used for CYCLONE unsupervised analysi
BackgroundCombining immune checkpoint therapy (ICT) and vascular endothelial growth factor inhibitors (VEGFi) may result in increased treatment-related and immune-related adverse events (TRAEs and irA